C型肝炎キャリア拾い上げにおいて，HCV抗体陽性者に対して残血清を用いたHCVコア抗原測定法併用の臨床的有用性-Reference-Cited by-同舟云学术

C型肝炎キャリア拾い上げにおいて，HCV抗体陽性者に対して残血清を用いたHCVコア抗原測定法併用の臨床的有用性

Published:2023-12-01 Issue:12 Volume:64 Page:603-609
ISSN:0451-4203
Container-title:Kanzo
language:en
Short-container-title:Acta hepatologica Japonica

Author:

Joshita Satoru¹,Yamashita Yuki¹,Usami Yoko²,Iwadare Takanobu¹,Okumura Taiki¹,Wakabayashi Shun-ichi¹,Kobayashi Hiroyuki¹,Sugiura Ayumi³,Kimura Takefumi¹,Umemura Takeji¹

Affiliation:

1. Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine

2. Department of Laboratory Medicine, Shinshu University Hospital

3. Department of Internal Medicine, Satoh Hospital

Publisher

Japan Society of Hepatology

Subject

Hepatology

Link

https://www.jstage.jst.go.jp/article/kanzo/64/12/64_603/_pdf

Reference23 articles.

1. 1) Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-675

2. 2) Maan R, van Tilborg M, Deterding K, et al. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 2016; 14: 1821-1830.e1826

3. 3) Joshita S, Sugiura A, Umemura T, et al. Clinical impact of normal alanine aminotransferase on direct-acting antiviral outcome in patients with chronic hepatitis C virus infection. JGH Open 2020; 4: 574-581

4. 4) Sugiura A, Joshita S, Umemura T, et al. Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals. J Viral Hepat 2018; 25: 1462-1471

5. 5) Sugiura A, Joshita S, Yamashita Y, et al. Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases. Biomedicines 2020; 8: 74